Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for major depressive disorder with high vs low inflammation
ACTRN12622000881730Phase 4Terminated
- Sponsor
- The University of Auckland
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of naltrexone in major depressive disorder (MDD) (5 arms), sponsored by The University of Auckland. Primary endpoint: Montgomery-Asberg Depression Rating Scale at week 12. Started Oct 2022; status: terminated.
02
Drugs
naltrexone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12622000881730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000881730.